Drug intelligence / Profile preview

sacituzumab tirumotecan + iparomlimab

Development stage: Unknown
Lead developer: Kelun-Biotech
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Sacituzumab tirumotecan + iparomlimab is an investigational combination regimen being evaluated for the treatment of locally advanced cervical cancer. Sacituzumab tirumotecan (also known as MK-2870 or SKB264) is a trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) featuring a belotecan-derivative topoisomerase I inhibitor payload (KL610023) attached via a hydrolytically-cleavable linker. Iparomlimab (QL1604) is a monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor. This combination, often administered alongside tuvonralimab (a CTLA-4 inhibitor), aims to leverage the cytotoxic effects of the ADC with the immune-potentiating effects of checkpoint inhibition to improve outcomes in neoadjuvant settings for cervical cancer.

Other names: sacituzumab tirumotecan + iparomlimab + tuvonralimab

Targets

TOP1 (DNA Topoisomerase I)TACSTD2 (Tumor-associated calcium signal transducer 2)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on sacituzumab tirumotecan + iparomlimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sacituzumab tirumotecan + iparomlimab.

Explore the full profile